Wall Street analysts expect Kala Pharmaceuticals (NASDAQ:KALA) to announce earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kala Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.41). The company is expected to issue its next earnings results on Monday, June 25th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.20) to ($1.74). For the next financial year, analysts expect that the company will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.96) to ($1.93). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Monday, March 26th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.09).
Kala Pharmaceuticals stock traded down $0.21 during midday trading on Tuesday, hitting $16.41. 74,303 shares of the company were exchanged, compared to its average volume of 224,987. The firm has a market cap of $402.96 and a price-to-earnings ratio of -2.81. Kala Pharmaceuticals has a fifty-two week low of $11.81 and a fifty-two week high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14.
In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc purchased 170,338 shares of the stock in a transaction on Wednesday, January 10th. The shares were bought at an average price of $12.83 per share, for a total transaction of $2,185,436.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired 1,108,150 shares of company stock worth $15,772,394 in the last quarter.
Hedge funds have recently modified their holdings of the business. Orbimed Advisors LLC purchased a new position in Kala Pharmaceuticals during the third quarter worth approximately $54,251,000. JPMorgan Chase & Co. purchased a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $4,037,000. Bank of New York Mellon Corp purchased a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $540,000. Crestline Management LP purchased a new position in shares of Kala Pharmaceuticals in the third quarter valued at approximately $888,000. Finally, Farallon Capital Management LLC lifted its position in shares of Kala Pharmaceuticals by 85.0% in the fourth quarter. Farallon Capital Management LLC now owns 185,000 shares of the company’s stock valued at $3,421,000 after acquiring an additional 85,000 shares in the last quarter. Institutional investors own 72.39% of the company’s stock.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.